Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Science Research Laboratory, Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- MKKPT9RCLJQ1
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Provided by Applicant): High dose chemotherapy is now a commonly
used approach for treatment of hematologic and other cancers, but causes severe
myelosuppression requiring progenitor cell infusions. Purging cancer cells from
infusions, while maintaining progenitor cells, is an important goal in
optimizing the curative potential of this technology. Current purging
techniques have limited efficiency and demand intensive time, technology and
cost. We have demonstrated a new technology that selectively kills larger cells
(including tumor cells) while preserving or enriching hematopoietic progenitor
cells, and does so rapidly, profoundly and inexpensively. In phase II, we will
apply this technology to a relevant hematologic cancer model (multiple
myeloma). Process parameters will be refined to achieve complete tumor purging
and progenitor cell preservation/enrichment from tumor-seeded blood or cord
blood cells. Sensitive and accurate cell enumeration will be achieved through
flow cytometry, tumor regrowth assays, real-time PCR, progenitor cell
quieseence/pluripotency assays, and in vivo hematopoietic reconstitution and
malignancy assessment in NOD/SCIDt,B2m about mice. We will then apply refined
parameters and assessment techniques to clinical volumes of bone marrow cells
from myeloma patients, utilizing an optimized, clinical-scale flowing process
apparatus. We anticipate the Phase III effort will involve Phase II clinical
trials supported by a major biomedical partner.
PROPOSED COMMERCIAL APPLICATION:
We expect PEF cell-size specific inactivation technology to be an effective transplant tissue purging strategy for post-intensive-therapy patient support. With the propose refinements and assessments, it should provide an approach for rapid, cost-effective, high purity isolation of stem cells from progenitor cell preparations, which will open research, clinical, gene therapy and stem cell banking markets. Our market analysis indicates that the total revenues for this technology may eventually reach $100 million per year.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
228 SBIR/STTR records share this UEI (1984–2020). Reported award amounts total $66,288,679. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Defense, Department of Energy, National Science Foundation, Department of Health and Human Services, National Aeronautics and Space Administration, Department of Transportation
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards